Anti-Oestrogen Therapy of Advanced Mammary Carcinoma
- 1 January 1976
- journal article
- research article
- Published by Taylor & Francis in Acta Radiologica: Therapy, Physics, Biology
- Vol. 15 (6), 513-518
- https://doi.org/10.3109/02841867609131975
Abstract
Forty mg daily of tamoxifen (Nolvadex) was administered orally to 89 patients with advanced soft tissue mammary carcinoma. At two months 43 per cent of the patients responded. At 6, 12 and 18 months, 42, 35 and 32 per cent, respectively, were still responding to therapy. The side effects were limited, fatique being the most frequent complaint. Oestrogen dependent side effects were not encountered. The therapeutic effect of tamoxifen is similar to that of oestrogen, but the side effects are less.Keywords
This publication has 9 references indexed in Scilit:
- Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptorEuropean Journal of Cancer (1965), 1975
- Antioestrogens in Treatment of Breast Cancer: Value of Nafoxidine in 52 Advanced CasesBMJ, 1974
- Hormone dependence in breast cancerMetabolism, 1974
- The influence of synthetic anti-estrogens on the binding of tritiated estradiol-17β by cytosols of human uterus and human breast carcinomaJournal of Steroid Biochemistry, 1973
- Hypothesis: Breast Cancer Regression under Oestrogen TherapyBMJ, 1973
- Anti-oestrogen Therapy for Breast Cancer: A Trial of Tamoxifen at Two Dose LevelsBMJ, 1973
- Clinical trial of nafoxidine, an oestrogen antagonist in advanced breast cancerEuropean Journal of Cancer (1965), 1972
- A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474British Journal of Cancer, 1971
- THE EXCRETION OF OESTRONE, PREGNANEDIOL AND PREGNANETRIOL IN BREAST CANCER PATIENTSActa Endocrinologica, 1963